Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
1-15 of 137

The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CEThe Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE In-Person & Virtual EventSpotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression

Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
- advertisement

The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape

Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders

Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma

Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma

Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
- advertisement

Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients

Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
CME/CEMenin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice































